길랭-바레증후군의 최신 지견

키워드

참고문헌 (90)

1. Asbury AK, "Assessment of current diagnostic criteria for Guillain-Barré syndrome", Ann Neurol, 27(Suppl), pp.S21~S24 (1990)
2. Kuwabara S, "Axonal Guillain-Barré syndrome : concepts and controversies", Lancet Neurol, 12, pp.1180~1188 (2013)
3. Wakerley BR, "Guillain-Barré and Miller Fisher syndromes--new diagnostic classification", Nat Rev Neurol, 10, pp.537~544 (2014)
4. Yuki N, "Guillain-Barré syndrome", N Engl J Med, 366, pp.2294~2304 (2012)
5. Chiba A, "Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome", Ann Neurol, 31, pp.677~679 (1992)
6. Koga M, "Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome", J Neuroimmunol, 86, pp.74~79 (1998)
7. Halstead SK, "Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model", Brain, 131, pp.1197~1208 (2008)
8. Kuwabara S, "Future treatment for Guillain-Barré syndrome", Clin Exp Neuroimmunol, 7, pp.320~323 (2016)
9. Guillain G, "Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquode cephalo-rachidien sans reaction cellulaire : remarques sur les caracteres cliniques et graphiques des reflexes tendineux", Bell Mem Soc Med Paris, 40, pp.1462~1470 (1916)
10. Wijdicks EF, "Guillain-Barré Syndrome", Mayo Clin Proc, 92, pp.467~479 (2017)
11. Doets AY, "Regional variation of Guillain-Barré syndrome", Brain, 141, pp.2866~2877 (2018)
12. Bae JS, "Guillain-Barré syndrome in Asia", J Neurol Neurosurg Psychiatry, 85, pp.907~913 (2014)
13. 김종국, "Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barré Syndrome in Korea: A Nationwide Multicenter Study", Journal of Clinical Neurology, 10(2), pp.94~100 (2014), 대한신경과학회[DOI]
14. Jacobs BC, "The spectrum of antecedent infections in Guillain-Barré syndrome : a case-control study", Neurology, 51, pp.1110~1115 (1998)
15. Cao-Lormeau VM, "Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia : a case-control study", Lancet, 387, pp.1531~1539 (2016)
16. Schonberger LB, "Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977", Am J Epidemiol, 110, pp.105~123 (1979)
17. Fiore AE, "Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices(ACIP), 2009", MMWR Recomm Rep, 58, pp.1~52 (2009)
18. Willison HJ, "Guillain-Barré syndrome", Lancet, 388, pp.717~727 (2016)
19. Asbury AK, "The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis", Medicine (Baltimore), 48, pp.173~215 (1969)
20. Macko CEH, "Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy", Ann Neurol, 39, pp.625~635 (1996)
21. Hartung HP, "T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome", Ann Neurol, 27(Suppl), pp.S57~S63 (1990)
22. Yuki N, "A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure", J Exp Med, 178, pp.1771~1775 (1993)
23. Koga M, "Antecedent infections in Fisher syndrome : a common pathogenesis of molecular mimicry", Neurology, 64, pp.1605~1611 (2005)
24. Houliston RS, "A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic", Biochemistry, 46, pp.8164~8171 (2007)
25. Ito M, "Bickerstaff 's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases", J Neurol, 255, pp.674~682 (2008)
26. Arai M, "Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without anti-GT1a IgG antibody", Muscle Nerve, 28, pp.246~250 (2003)
27. 김종국, "Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome", Journal of Clinical Neurology, 14(3), pp.401~406 (2018), 대한신경과학회[DOI]
28. Kaida K, "Ganglioside complexes as new target antigens in Guillain-Barrésyndrome", Ann Neurol, 56, pp.567~571 (2004)
29. 허소영, "A Variant Guillain-Barré Syndrome with Anti-Ganglioside Complex Antibody", Journal of Neurocritical Care, 11(2), pp.134~136 (2018), 대한신경집중치료학회[DOI]
30. Kimachi T, "Paraparetic Guillain-Barré syndrome : nondemyelinating reversible conduction failure restricted to the lower limbs", Muscle Nerve, 55, pp.281~285 (2017)
31. van Doorn PA, "Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome", Lancet Neurol, 7, pp.939~950 (2008)
32. Sejvar JJ, "Population incidence of Guillain-Barré syndrome : a systematic review and meta-analysis", Neuroepidemiology, 36, pp.123~133 (2011)
33. Fokke C, "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria", Brain, 137, pp.33~43 (2014)
34. Feasby TE, "Severe axonal degeneration in acute Guillain-Barré syndrome : evidence of two different mechanisms", J Neurol Sci, 116, pp.185~192 (1993)
35. Visser LH, "Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré study group", Brain, 118(Pt 4), pp.841~847 (1995)
36. Ruts L, "Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome : a prospective study", Neurology, 74, pp.1680~1686 (2010)
37. Capasso M, "Involvement of sensory fibres in axonal subtypes of Guillain-Barré syndrome", J Neurol Neurosurg Psychiatry, 82, pp.664~670 (2011)
38. Hadden RD, "Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange", sandoglobulin Guillain-Barré syndrome trial group, 1998, pp.44, 780~788
39. 신진홍, "길랑-바레 증후군의 전기생리학적 분류 - 전기생리학적 소견의 시기적 변화 -", 대한신경과학회지, 20(6), pp.630~633 (2002), 대한신경과학회
40. Kim JD, "Clinical characteristics of the subtypes of Guillain-Barré syndrome according to the electrodiagnostic criteria", J Korean Neurol Assoc, 19, pp.503~508 (2001)
41. Capasso M, "Acute motor conduction block neuropathy another Guillain-Barrésyndrome variant", Neurology, 61, pp.617~622 (2003)
42. Susuki K, "Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers", J Neurosci, 27, pp.3956~3967 (2007)
43. Kokubun N, "Conduction block in acute motor axonal neuropathy", Brain, 133, pp.2897~2908 (2010)
44. Susuki K, "Dysfunction of nodes of Ranvier : a mechanism for anti-ganglioside antibody-mediated neuropathies", Exp Neurol, 233, pp.534~542 (2012)
45. Fisher M, "An unusual variant of acute idiopathic polyneuritis(syndrome of ophthalmoplegia, ataxia and areflexia)", N Engl J Med, 255, pp.57~65 (1956)
46. Funakoshi K, "Clinical predictors of mechanical ventilation in Fisher", Guillain-Barré overlap syndrome, 2009, pp.80, 60~64
47. Lee SH, "Acute ophthalmoplegia(without ataxia)associated with anti-GQ1b antibody", Neurology, 71, pp.426~429 (2008)
48. Uchibori A, "Ca(2+)-dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders", J Neuroimmunol, 298, pp.172~177 (2016)
49. Odaka M, "Anti-GQ1b IgG antibody syndrome : clinical and immunological range", J Neurol Neurosurg Psychiatry, 70, pp.50~55 (2001)
50. 김종국, "항-GQ1b 항체증후군; Miller Fisher 증후군의 다른 이름인가, 새로운 증후군의 출현인가?", 대한신경과학회지, 27(4), pp.307~312 (2009), 대한신경과학회
51. Ryu WY, "Pattern of extraocular muscle involvements in Miller Fisher syndrome", J Clin Neurol
52. Ueno T, "Unilateral oculomotor nerve palsy following Campylobacter infection : a mild form of Miller Fisher syndrome without ataxia", Intern Med, 56, pp.2929~2932 (2017)
53. Bae JS, "Bilateral internal ophthalmoplegia as an initial sole manifestation of Miller Fisher syndrome", J Clin Neurosci, 16, pp.963~964 (2009)
54. Pan CL, "Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody", Neurology, 57, pp.1316~1318 (2001)
55. Kusunoki S, "Experimental sensory neuropathy induced by sensitization with ganglioside GD1b", Ann Neurol, 39, pp.424~431 (1996)
56. Kim JK, "Acute bulbar palsy as a variant of Guillain-Barré syndrome", Neurology, 86, pp.742~747 (2016)
57. Kim SY, "Polycranial neuropathy and sensory ataxia with IgG anti-GD1a antibody as a variant of Guillain-Barré syndrome", J Clin Neurosci, 20, pp.473~475 (2013)
58. Susuki K, "A Guillain-Barré syndrome variant with prominent facial diplegia", J Neurol, 256, pp.1899~1905 (2009)
59. Kim JK, "When is facial diplegia regarded as a variant of Guillain-Barré syndrome", J Peripher Nerv Syst, 20, pp.32~36 (2015)
60. Zaeem Z, "Autonomic involvement in Guillain-Barré syndrome: an update", Clin Auton Res (2018)
61. Chen A, "Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome", J Clin Neurosci, 22, pp.914~916 (2015)
62. Shiraiwa N, "Miller Fisher syndrome with sinus arrest", Neurol Int, 9, pp.7312~ (2017)
63. Asahina M, "Autonomic function in demyelinating and axonal subtypes of Guillain-Barré syndrome", Acta Neurol Scand, 105, pp.44~50 (2002)
64. Sejvar JJ, "Guillain-Barré syndrome and Fisher syndrome : case definitions and guidelines for collection, analysis, and presentation of immunization safety data", Vaccine, 29, pp.599~612 (2011)
65. Choe YJ, "Guillain-Barré syndrome following receipt of influenza A(H1N1)2009 monovalent vaccine in Korea with an emphasis on Brighton collaboration case definition", Vaccine, 29, pp.2066~2070 (2011)
66. Wakerley BR, "Clinical classification of 103 Japanese patients with Guillain-Barrésyndrome", J Neurol Sci, 369, pp.43~47 (2016)
67. Cornblath DR, "Motor conduction studies in Guillain-Barré syndrome : description and prognostic value", Ann Neurol, 23, pp.354~359 (1988)
68. Vucic S, "Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy", Clin Neurophysiol, 115, pp.2329~2335 (2004)
69. Derksen A, "Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics", Muscle Nerve, 50, pp.780~784 (2014)
70. Uncini A, "Electrodiagnostic criteria for Guillain-Barrèsyndrome : a critical revision and the need for an update", Clin Neurophysiol, 123, pp.1487~1495 (2012)
71. 구용서, "Early Electrodiagnostic Features of Upper Extremity Sensory Nerves Can Differentiate Axonal Guillain-Barré Syndrome from Acute Inflammatory Demyelinating Polyneuropathy", Journal of Clinical Neurology, 12(4), pp.495~501 (2016), 대한신경과학회[DOI]
72. Pyun SY, "Early discrimination of sensorimotor Guillain-Barré syndrome into demyelinating or axonal subtype by automated nerve excitability testing", J Peripher Nerv Syst, 22, pp.85~91 (2017)
73. The Guillain-Barré syndrome Study Group, "Plasmapheresis and acute Guillain-Barré syndrome", Neurology, 35, pp.1096~1104 (1985)
74. Hughes RAC, "Intravenous immunoglobulin for Guillain-Barré syndrome", Cochrane Database Syst Rev, 46, pp.CD002063~ (2014)
75. Korinthenberg R, "Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome : a randomized trial", Pediatrics, 116, pp.8~14 (2005)
76. "Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma exchange", sandoglobulin Guillain-Barré syndrome trial group, 1997, pp.349, 225~230
77. Verboon C, "Treatment dilemmas in Guillain-Barré syndrome", J Neurol Neurosurg Psychiatry, 88, pp.346~352 (2017)
78. Wang YZ, "Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome", Sci Rep, 5, pp.13931~ (2015)
79. Walgaard C, "Second IVIg course in Guillain-Barré syndrome patients with poor prognosis(SID-GBS trial) : protocol for a double-blind randomized, placebo-controlled clinical trial", J Peripher Nerv Syst, 23, pp.210~215 (2018)
80. Mori K, "Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS", Neurology, 58, pp.979~982 (2002)
81. 강성진, "길랑-바레 증후군의 양상으로 나타난 만성염증수초탈락여러신경병증", Annals of Clinical Neurophysiology, 10(1), pp.70~73 (2008), 대한임상신경생리학회
82. Davidson AI, "Inhibition of complement in Guillain-Barré syndrome : the ICA-GBS study", J Peripher Nerv Syst, 22, pp.4~12 (2017)
83. Misawa S, "Safety and efficacy of eculizumab in Guillain-Barré syndrome : a multicentre, double-blind, randomised phase 2 trial", Lancet Neurol, 17, pp.519~529 (2018)
84. McGonigal R, "C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy", Acta Neuropathol Commun, 4, pp.23~ (2016)
85. Netto AB, "Mortality in mechanically ventilated patients of Guillain-Barré Syndrome", Ann Indian Acad Neurol, 14, pp.262~266 (2011)
86. van Koningsveld R, "A clinical prognostic scoring system for Guillain-Barrésyndrome", Lancet Neurol, 6, pp.589~594 (2007)
87. Bae JS, "Diabetes mellitus exacerbates the clinical and electrophysiological features of Guillain-Barré syndrome", Eur J Neurol, 23, pp.439~446 (2016)
88. Halstead SK, "Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes", Neurol Neuroimmunol Neuroinflamm, 3, pp.e284~ (2016)
89. Kaida K, "Anti-ganglioside complex antibodies in Miller Fisher syndrome", J Neurol Neurosurg Psychiatry, 77, pp.1043~1046 (2006)
90. Morikawa M, "Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies", J Neuroimmunol, 301, pp.35~40 (2016)